24/7 Market News Snapshot 21 July, 2025 – ProMIS Neurosciences Inc. Common Shares (ON) (NASDAQ:PMN)

July 21, 2025

DENVER, Colo., 21 July, 2025 (www.247marketnews.com) – (Nasdaq:PMN) are discussed in this article.
ProMIS Neurosciences Inc. (Nasdaq:PMN), recognized for its commitment to developing innovative therapeutic antibodies for neurodegenerative disorders, is experiencing noteworthy momentum in the market. The company’s shares surged 127.68% in pre-market trading, reaching $1.002, up from $0.440, reflecting a significant uptick in investor interest. The dramatic rise was accompanied by a trading volume of 32.89 million shares, indicative of heightened enthusiasm surrounding ProMIS’s advancements in its neurotherapeutics pipeline.

This surge comes on the heels of an important recognition by the U.S. Food and Drug Administration (FDA), which granted Fast Track designation to PMN’s lead candidate, PMN310. This designation is reserved for therapeutic programs addressing critical unmet medical needs, facilitating a more streamlined and collaborative development process with the FDA. Neil Warma, the President and CEO, highlighted this milestone as a pivotal moment for both the company and the broader Alzheimer’s disease (AD) community. He noted that PMN310 aims to offer a safer and more effective treatment alternative for AD patients, potentially alleviating the adverse side effects linked with current therapies.

PMN310 is specifically designed as a humanized monoclonal antibody that targets toxic oligomers of amyloid-beta while avoiding binding to less harmful forms. The ongoing PRECISE-AD Phase 1b trial is assessing its safety, tolerability, and pharmacokinetics in early-stage AD patients, with interim biomarker results expected by mid-2026. As over 6 million Americans currently live with Alzheimer’s, the need for innovative therapeutic solutions has never been more pressing. With its promising candidates and recent regulatory support, ProMIS Neurosciences stands poised to make a significant impact in the evolving landscape of Alzheimer’s treatment.

Related news for (PMN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.